INVEX Therapeutics Ltd (ixc) Logo

INVEX Therapeutics Ltd (IXC)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

IXC Chart

IXC's Principal Activity is the biopharmaceuticals.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -18.62%
vs ASX 200 (1yr) -56.02%

Size

Market Capitalisation
ASX Rank 1435 of 2,564
Sector Rank 121 of 177

Key Information

Shares Issued
Sector Healthcare
Similar Companies CGB / ACR / BIT
EPS -$0.054
DPS $0.00
NTA per share $0.44

Broker Consensus

IXC is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Invex Therapeutics Ltd (IXC) is a biopharmaceutical company focused on the repurposing of an approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Subiaco WA 6008
Website www.invextherapeutics.com
Registry Automic Group
Auditor BDO Audit (WA) Pty Ltd
Date Listed 5 Jul 2019

Upcoming Calendar

Date Event
27/08/2021 Report (Prelim)
27/08/2021 Report (Annual)
14/02/2022 Report (Interim)

Dividend History

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Megan Baldwin Non-Executive Director Feb 2021 Director Bio icon

Dr Megan Baldwin

Non-Executive Director

Dr Baldwin is an experienced biotechnology executive, having over 20 years' experience working on therapeutic drug development programs for cancer and ophthalmic indications. Dr Baldwin is CEO and Managing Director of Opthea Limited (ASX: OPT; NASDAQ: OPT), a biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of retinal eye diseases, including wet age-related macular degeneration (wet AMD). Under Dr Baldwin's leadership, Opthea has advanced its ophthalmology program through Phase I and Phase II clinical development. It was added to the S&P/ASX 300 in June 2020 and in October 2020 completed initial public offering (IPO) and listing on the US NASDAQ exchange to progress two pivotal Phase III studies in wet AMD. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a postdoctoral researcher before moving to Genentech's commercial division. Dr Baldwin also serves on the Board of Ausbiotech as Deputy Chair.

Dr Thomas (Tom) Duthy Executive Director Oct 2020 Director Bio icon

Dr Thomas (Tom) Duthy

Executive Director

Dr Duthy has financial market experience, combined with his senior executive experience at the S&P/ASX Top 100 Company level and involvement in corporate transactions within the sector. Dr Duthy is currently the CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations (IR) firm based in Adelaide, Australia. Dr Duthy was formerly the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (Sirtex), which was sold to CDH Investments in September 2018. He currently advises several ASX Listed companies in both IR and Corporate Development roles. Prior to Sirtex, Dr Duthy spent ten years as a sell-side Healthcare & Biotechnology analyst focused mainly on small cap companies. Dr Duthy is currently a Non-Executive Director of Respiri Limited.

Dr Alexandra J Sinclair Chief Scientific Officer,Executive Director Jun 2019 Director Bio icon

Dr Alexandra J Sinclair

Chief Scientific Officer,Executive Director

Dr Sinclair is a Clinician Scientist and Neurology Consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham, UK.

Mrs Narelle Warren Chief Financial Officer,Company Secretary Mar 2019 Director Bio icon

Mrs Narelle Warren

Chief Financial Officer,Company Secretary

Ms Warren has over twenty years of corporate advisory, financial management and company secretarial experience. Ms Warren has co-ordinated and assisted in a number of corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.

Mr David McAuliffe Non-Executive Director Mar 2019 Director Bio icon

Mr David McAuliffe

Non-Executive Director

Mr McAuliffe has over twenty years' experience in the international biotechnology field. He has been involved in capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France and the United Kingdom, many of which have become public companies. He is President of the Dyslexia-Speld Foundation WA (Inc). Mr McAuliffe is a current director of ASX listed 4DS Memory Ltd.

Dr Jason Loveridge Non-Executive Chairman,Non-Executive Director Mar 2019 Director Bio icon

Dr Jason Loveridge

Non-Executive Chairman,Non-Executive Director

Dr Loveridge is a founder of Invex and currently CEO of 4SC AG, a Frankfurt (Germany) listed oncology company. He has more than thirty years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. Additionally, he has transactional experience in the sale and partnering of biotechnology assets.

Director Transactions

IXC directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
08/04/21 Megan Baldwin Issued 400,000 $0.775 $310,000 Issue of options
18/11/20 Thomas (Tom) Duthy Issued 800,000 $0.805 $644,000 Issue of options
22/11/19 Alexandra Sinclair Issued 800,000 $0.71 $568,000 Issue of options
22/11/19 David McAuliffe Issued 200,000 $0.71 $142,000 Issue of options
22/11/19 Jason Loveridge Issued 800,000 $0.71 $568,000 Issue of options
22/11/19 Narelle Warren Issued 400,000 $0.71 $284,000 Issue of options

Director Interests

The current holdings of IXC directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Megan Baldwin 08/04/2021 0 N/A 400,000 N/A
Thomas (Tom) Duthy 18/11/2020 N/A 106,923 800,000 N/A
Narelle Warren 01/10/2020 N/A 200,000 400,000 N/A
Alexandra Sinclair 30/06/2020 2,500,000 N/A N/A N/A
Jason Loveridge 30/06/2020 3,336,000 N/A N/A N/A
David McAuliffe 30/06/2020 3,350,001 N/A N/A N/A

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Aug 27, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Tattarang Pty Ltd 13,841,670 23.45%
Tisia Nominees Pty Ltd 5,000,000 8.47%
Jk Nominees Pty Ltd 2,820,896 4.78%
Anthony Grist 1,690,000 2.86%
Dr Jason Loveridge 1,561,729 2.65%
Mr David Jerimiah Mcauliffe 1,150,000 1.95%
HSBC Custody Nominees (Australia) Limited 1,041,667 1.76%
Alexandra Jean Sinclair 933,334 1.58%
Ms Kathryn Mary Salkilld 650,000 1.10%
Citicorp Nominees Pty Ltd 600,000 1.02%
The University Of Birmingham 590,000 1.00%
Sunset Capital Management Pty Ltd 500,000 0.85%
Bannaby Investments Pty Limited 500,000 0.85%
Bnp Paribas Nominees Pty Ltd Hub 24 Custodial Serv Ltd Drp 482,500 0.82%
Cityscape Asset Pty Ltd 455,000 0.77%
Hsbc Custody Nominees (Australia) Limited-Gsi Eda 430,000 0.73%
Sandhurst Trustees Ltd 425,584 0.72%
Hsbc Custody Nominees (Australia) Limited-Gsi Eda I 400,000 0.68%
J P Morgan Nominees (Australia Limited 400,000 0.68%
Cs Third Nominees Pty Limited 375,000 0.64%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 274 416 184 357 86 1,317

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Tattarang Pty Ltd 27/08/2020 8,846,154 11.77
Tisia Nominees Pty Ltd 27/08/2020 4,000,000 5.32

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
28-05-20 Tattarang Pty Ltd 2,390,057 9.09 10.95

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
01-12-20 JK Nominees Pty Ltd 4,000,000 5.92 --
02-07-20 Anthony J Grist 3,543,750 5.25 --
28-05-20 Anthony J Grist 456,250 7.27 5.25

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $1.30 30 June
Page Icon
IXC Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.